



Stock Symbol: **CLCS**



Overview Q2 | 2026

Immunotherapy Innovations for Safer
and More Effective Treatment of Cancer
and Other Diseases



Safe Harbor Statement

With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.





Introduction Q2 | 2026





Cell Source is an innovative biotechnology company focused on developing breakthrough cell therapy treatments based on the management of immune response.

The company's patented **Veto Cell** technology* represents a major breakthrough in making immune response "selective".

Veto Cell technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific "desirable" foreign cells and tissue while continuing to attack all other potential threats.

* Licensed exclusively from the Weizmann Institute of Science



Cell Source's Areas of Focus

Cell Therapy

Part of a new wave of medicine using living whole human cells instead of synthetic chemical compounds to treat disease. Known mostly for use in bone marrow transplantation, cell therapy is now moving into the mainstream for the treatment of a broader set of diseases including a variety of cancers.

Immunotherapy

An area within cell therapy that involves using the immune system, whose role is normally to reject foreign incursions, to instead directly treat disease.




Cell Source's Unique, Proprietary Veto Cell Technologies*

Today, in order to coax the body into accepting organ transplants and other treatments, doctors must suppress the patient's entire immune system using radiation and chemotherapy, leaving the patient vulnerable to infection.

Cell Source's Veto Cells enable doctors to selectively manage patients' immune system responses, facilitating the treatment of a broad range of diseases that effect millions of people: targeted therapies for bone marrow and organ transplants, cancer treatments, and treating other severe ailments.

Cell Source's Veto cell technology allows transplants to be accepted while leaving the rest of the immune system intact.





Applications: Stem Cell* Transplants

Bone marrow transplants are an important treatment for cancer and other diseases. Today, roughly 50,000 patients worldwide receive donor-derived** bone marrow transplants each year, and mortality rates are very high due to transplant-related complications.

Veto Cell treatments are expected to significantly broaden the use of this life-saving treatment by enabling mismatched donors and otherwise making stem cell transplants safer and more accessible, enabling older or weaker patients to benefit from this potentially life-saving treatment.

* Includes bone marrow transplants

** Known as "allogeneic" - as opposed to patient-derived "autologous" transplants





Applications: Organ Transplants

Patients today need to find fully matched donors (many die while on waiting lists) and, even when successful, transplant patients require lifelong, daily anti-rejection therapy which weakens the immune system, impairs quality of life, and reduces life expectancy.

Veto cell treatment can make donor mismatched kidney transplants available to a far broader pool of patients and potentially eliminate the need for lifelong, daily post-transplant anti-rejection treatments, thus improving life quality, reducing cost of care, and increasing life expectancy.



Applications: Cancer Treatment Therapies

CAR-T cell therapy, a very promising emerging cancer treatment, is currently confined to the niche of “personalized medicine” – using the patient’s own cells, which makes the treatments very expensive (over \$650,000 per treatment) and causes safety and quality control problems. The vision for this game-changing breakthrough in cancer treatment is for it to become a universal, off-the-shelf product that can enjoy drug-like distribution economics.

Based on preclinical trials combining Veto Cells with CAR-T cells, Veto CAR-T combined therapy has the potential to turn CAR-T into a successful off-the-shelf treatment, initially for blood cancer and eventually for solid tumors. Furthermore, by combining Veto with CAR-T, we can bridge between the time of the stem cell transplant (using the CAR-T to protect the patient from relapse) to the successful constitution of a new immune system (offering long-term relapse protection), thus providing a distinctive end-to-end solution with the potential to significantly increase long-term survival for cancer patients.



What is an allogeneic stem cell transplant?

Stem cells are transplanted from a healthy donor. They can be derived from either bone marrow or other sources. These blood-forming cells build a new, healthy immune system in the patient that can then perform immune functions properly, leading to prevention of cancer or correction of immune system related diseases.

How is the transplant performed?

- The patient undergoes “conditioning” treatment (chemotherapy and/or radiation) to kill the diseased cells and make room for the stem cells to grow a new immune system.
- The healthy stem cells are administered via an intravenous (IV) infusion.

What are the risks?

- While the immune system is reconstituted (rebuilt) the patient is susceptible to numerous risks, including cancer relapse, viral infections, and GvHD (Graft vs. Host Disease - where the transplanted cells reject the patient) – all of these potential complications bring with them a significant risk of mortality during the first few months after the transplant.





Safer and more effective treatments for cancer and organ failure

Veto CAR-T:

A comprehensive, long-term treatment for blood cell cancers.

Cell Source is developing a proprietary process to make donor cells and even whole organs universally acceptable to recipients, bypassing the body's typical immune response to foreign tissue.

The goal of Veto CAR-T cell therapy is to provide engraftment under mild immune suppression – while avoiding cancer relapse, GvHD and viral infections – thus combining the proven cancer killing power of CAR-T with the immune reconstitution capabilities of Veto Cells, thereby delivering a holistic approach to the treatment of blood cancer.

Veto Cell Technologies:

Overcoming transplant rejection.

Veto Cells can also be used in organ transplantation in order to allow for mismatched donors. By causing the patient's reconstituted immune system to permanently tolerate the donor's tissue, this not only broadens the donor pool, it can also eliminate the current need for lifelong daily anti-rejection therapy post-transplantation.





World-Class Technology Meets Tremendous Opportunity.

Cell Source is poised to capitalize on growing market opportunities including the \$80 billion global blood cancer therapeutics market (2025)* and the \$50 billion global organ and tissue transplantation market (2025)**. In preclinical trials, Cell Source's Veto Cell technology has significantly increased success rates of donor-mismatched bone marrow transplantations under mild levels of immune suppression, while preventing both GvHD and infections. The company is currently pioneering its Anti-viral Veto Cell therapy for cancer treatment and is conducting a Phase 1/2 clinical trial at University of Texas MD Anderson Cancer Center (MDACC) in Houston, the highest rated cancer treatment hospital in America.

Cell Source's technology was invented by Professor Yair Reisner and his team at the internationally-recognized Weizmann Institute of Science, one of Israel's leading scientific research centers, where he served as the Head of Immunology. Cell Source holds the exclusive worldwide license to Professor Reisner's Veto Cell technology, which is owned by the Weizmann Institute.

In addition to his role as Cell Source's Scientific Advisory Board Chairman, Professor Reisner serves as the Director of Stem Cell Research at the Department of Stem Cell Transplantation, Division of Cancer Medicine, at MDACC, where he also heads the Reisner Laboratory. He was recently awarded \$10 million in grants in Texas (including a grant from The Cancer Prevention & Research Institute of Texas and matching funding from MDACC and the University of Texas).

Cell Source's prestigious Scientific Advisory Board includes national leaders in transplantation and cancer treatment from Stanford University (CA), City of Hope (CA), Mount Sinai Medical Center (NY), University of Oxford (UK), and The University of Wurzburg (Germany).

*Source: The Business Research Company: Blood Cancer Drugs Global Market Report 2026

**Source: Precision Business Insights; Organ and Tissue Transplantation Market Size, Share, Growth, Trends, and Global Industry Analysis, September 2025





Stock Symbol: CLCS

**Thank you for your
time and interest.**

www.cell-source.com